My research asks how changes in neural function affect behaviour and reveal opportunities for treatment. It connects basic neuroscience with disease modelling and drug discovery.
We use
genetically defined zebrafish models to study the effects of disease-associated
genes. Automated behavioural analysis allows us to measure those effects and
test compounds that may modify them. Electrophysiology and molecular profiling
help us understand the biological changes behind the behaviour.
Our work
includes models relevant to ADHD and schizophrenia, alongside earlier studies
of other neurological disorders. We compare responses with established
treatments and use complementary models and human evidence to assess which
findings warrant further investigation.
Through 3Z
Pharmaceuticals, we use this approach to build clinically relevant, patentable
assets with a practical development path.
Our ADHD
research began with behavioural screening in an adgrl3.1 mutant zebrafish
model. This work identified compounds that reduced hyperactivity, including
amlodipine. Subsequent studies combined evidence from zebrafish and rats with
human genetic analyses and observational data.
The findings
support further investigation of amlodipine and L-type calcium channel biology
in ADHD. They provide a basis for clinical testing; efficacy in people with
ADHD remains to be established.
The development
programme is now focused on S-amlodipine, also known as levamlodipine, and is
being advanced through LTCC.
My early
research examined the neural mechanisms of sleep and its development. This work
continues to inform my interest in neuronal excitability and the relationship
between brain activity and behaviour.
Alongside drug
discovery, I continue collaborative studies of whale and dolphin brains. We
examine how their structure compares with that of other mammals, including the
hippocampus and neural systems involved in sleep and arousal. This work
addresses basic questions about brain organisation and evolution.
I am interested
in using computational methods to analyse behavioural and molecular data and
improve the choice of experiments. The approach I want to develop links
prediction with testing: models nominate candidates, experiments test them, and
results improve subsequent predictions.
At Reykjavík
University, I connect research with teaching in neuroscience and
neurotechnology. I also contribute to laboratory teaching through the
NeurotechEU EMN master’s pathway.
Students and
interns regularly contribute to all our research programmes. Their projects
span disease modelling, behavioural measurement, electrophysiology, molecular
and computational analysis, and comparative neuroanatomy.
For research
collaborations, student projects or internship enquiries, contact
karlsson@ru.is.